- Shares of Verve Therapeutics are up 13% in late Tuesday afternoon trading following the release of preclinical data on VERVE-201 for a type of genetically high cholesterol (homozygous familial hypercholesterolemia).
- VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, which is a key regulator of cholesterol and triglyceride metabolism.
- In a primate study, a surrogate version of VERVE-201 demonstrated strong liver ANGPTL3 editing ranging from 54%-57% and reductions in blood ANGPTL3 protein ranging from 95-98% across three dose levels.
- The company, which is focused on gene therapies for cardiovascular diseases, said it is looking at bringing VERVE-201 into the clinic in 2024.
- Check out Seeking Alpha contributor Derek Lowe's analysis of Verve's ( NASDAQ: VERV ) lead candidate, VERVE-101, also for homozygous familial hypercholesterolemia, which targets the PCSK9 gene.
For further details see:
Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate